Targeting kidney fibrosis by a novel myofibroblast specific small molecule inhibitor
FibroTarg aims to evaluate the feasibility of Fibrolisine, an innovative anti-fibrotic drug, to halt kidney fibrosis and progression to end-stage renal disease in chronic kidney disease patients.
Projectdetails
Introduction
Chronic kidney disease (CKD) is a progressive disease that is prevalent in 10% of the developed world and develops as a result of diabetes mellitus, hypertension, glomerulonephritis, or acute kidney injury. Over time, CKD can progress to end-stage renal disease (ESRD); a condition that can only be treated through hemodialysis or kidney transplantation, posing a severe medical, societal, and economic challenge.
Pathological Mechanism
Fibrosis is recognized as a key pathological mechanism in CKD, responsible for slowly destroying the tissue architecture of the kidney. Current therapies for CKD alleviate symptoms of the disease by controlling hypertension and hyperglycemia. However, while fibrosis is a promising therapeutic target, no antifibrotic therapy for the kidney has reached the clinic. Hence, there is an urgent need for disease-modifying and curative treatments that can halt fibrosis.
Project Overview
In FibroTarg, we will assess the technical and commercial feasibility of Fibrolisine, a first-of-its-kind anti-fibrotic drug candidate, for the treatment of CKD. Our preliminary data has confirmed a unique expression profile of our therapeutic target and reduced fibrosis onset in in vivo knockout models without side effects after kidney injury.
Expected Outcomes
Hence, Fibrolisine is expected to target the process of fibrogenesis and halt the progression to ESRD in early-stage CKD patients. Through the activities in the FibroTarg project, we aim to:
- Demonstrate the antifibrotic potential of Fibrolisine in advanced human kidney fibrosis organoid models.
- Assess its efficacy in in vivo models of kidney injury.
- Investigate the commercial potential of Fibrolisine by analyzing the commercial landscape and developing an initial commercialization strategy.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-10-2023 |
Einddatum | 31-3-2025 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UNIVERSITAETSKLINIKUM AACHENpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Identification of novel diagnostic, predictive and therapeutic strategies in chronic kidney diseaseTargetCKD aims to revolutionize chronic kidney disease management by developing noninvasive diagnostics and novel therapeutics through advanced genomic technologies and interdisciplinary research. | ERC Consolid... | € 1.999.063 | 2022 | Details |
Preventing Alport syndrome with a natural amino acidRENOTREAT aims to treat Alport syndrome by using a natural amino acid to induce tubular proteinuria, potentially slowing CKD progression and improving patient outcomes through preclinical and clinical trials. | ERC Proof of... | € 150.000 | 2024 | Details |
Early detection, molecular mechanisms and therapeutic interventions in chronic kidney diseaseELIMINATE-CKD aims to enhance chronic kidney disease detection by developing a method to quantify nephron number using multi-omics and machine learning for improved diagnostics and therapies. | ERC Consolid... | € 2.000.000 | 2024 | Details |
Deciphering the genetic basis of chronic kidney disease towards prevention and personalized therapyThis project aims to uncover the genetic basis of chronic kidney disease (CKD) through next-generation sequencing and develop RNA-based therapies for targeted treatment and improved management. | ERC Starting... | € 1.800.000 | 2022 | Details |
Decode and Cure primary Focal Segmental GlomerulosclerosisCureFSGS aims to develop a molecular classification and targeted therapies for Focal Segmental Glomerulosclerosis using advanced analytics and immune mapping to improve treatment outcomes. | ERC Advanced... | € 2.500.000 | 2025 | Details |
Identification of novel diagnostic, predictive and therapeutic strategies in chronic kidney disease
TargetCKD aims to revolutionize chronic kidney disease management by developing noninvasive diagnostics and novel therapeutics through advanced genomic technologies and interdisciplinary research.
Preventing Alport syndrome with a natural amino acid
RENOTREAT aims to treat Alport syndrome by using a natural amino acid to induce tubular proteinuria, potentially slowing CKD progression and improving patient outcomes through preclinical and clinical trials.
Early detection, molecular mechanisms and therapeutic interventions in chronic kidney disease
ELIMINATE-CKD aims to enhance chronic kidney disease detection by developing a method to quantify nephron number using multi-omics and machine learning for improved diagnostics and therapies.
Deciphering the genetic basis of chronic kidney disease towards prevention and personalized therapy
This project aims to uncover the genetic basis of chronic kidney disease (CKD) through next-generation sequencing and develop RNA-based therapies for targeted treatment and improved management.
Decode and Cure primary Focal Segmental Glomerulosclerosis
CureFSGS aims to develop a molecular classification and targeted therapies for Focal Segmental Glomerulosclerosis using advanced analytics and immune mapping to improve treatment outcomes.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
Haalbaarheid Renal Tracker+Het project onderzoekt de haalbaarheid van de Renal Tracker+, een serviceproduct dat nierpatiënten helpt om de impact van levensstijlveranderingen op hun ziekte te monitoren. | Mkb-innovati... | € 20.000 | 2020 | Details |
Ontwikkeling van een diagnostische test voor de vroege detectie van chronische nierschadeDit project onderzoekt de ontwikkeling van een niet-invasieve test voor de vroege detectie van chronische nierschade. | Mkb-innovati... | € 18.067 | 2024 | Details |
Targeting OGG1 in Idiopathic Pulmonary FibrosisThe TOPFIBRO project aims to advance OXC-201, a novel IPF treatment, through efficacy validation, safety assessments, and regulatory preparations for first-in-human studies, targeting a market launch. | EIC Transition | € 2.499.998 | 2023 | Details |
breakthrough technologies for an implantable artificial kidneyKIDNEW aims to develop a modular implantable artificial kidney using innovative technologies for improved, cost-effective kidney replacement therapy without immunosuppressive drugs. | EIC Pathfinder | € 3.293.227 | 2023 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
Haalbaarheid Renal Tracker+
Het project onderzoekt de haalbaarheid van de Renal Tracker+, een serviceproduct dat nierpatiënten helpt om de impact van levensstijlveranderingen op hun ziekte te monitoren.
Ontwikkeling van een diagnostische test voor de vroege detectie van chronische nierschade
Dit project onderzoekt de ontwikkeling van een niet-invasieve test voor de vroege detectie van chronische nierschade.
Targeting OGG1 in Idiopathic Pulmonary Fibrosis
The TOPFIBRO project aims to advance OXC-201, a novel IPF treatment, through efficacy validation, safety assessments, and regulatory preparations for first-in-human studies, targeting a market launch.
breakthrough technologies for an implantable artificial kidney
KIDNEW aims to develop a modular implantable artificial kidney using innovative technologies for improved, cost-effective kidney replacement therapy without immunosuppressive drugs.